Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.

被引：6
|
作者：
Antonarakis, Emmanuel S.
Goh, Jeffrey C.
Gross-Goupil, Marine
Vaishampayan, Ulka N.
Piulats, Josep M.
De Wit, Ronald
Alanko, Tuomo
Fukasawa, Satoshi
Tabata, Kenichi
Feyerabend, Susan
Berger, Raanan
Wu, Haiyan
Kim, Jeri
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[3] Univ Hosp Bordeaux, Bordeaux, France
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Hosp Duran & Reynals, Inst Catalan Oncol, Barcelona, Spain
[6] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[7] Docrates Canc Ctr, Helsinki, Finland
[8] Chiba Canc Ctr, Chiba, Japan
[9] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[10] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[11] MSD China, Beijing, Peoples R China
[12] Merck & Co Inc, Kenilworth, NJ USA
[13] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.216
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
216
引用
收藏
页数：2
相关论文
共 50 条
  • [41] An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
    Carles, Joan
    Pichler, Angelika
    Korunkova, Hana
    Tomova, Antoaneta
    Ghosn, Marwan
    El Karak, Fadi
    Makdessi, Joseph
    Koroleva, Irina
    Barnes, Gisoo
    Bury, Denise
    Ozatilgan, Ayse
    Hitier, Simon
    Katolicka, Jana
    BJU INTERNATIONAL, 2019, 123 (03) : 456 - 464
  • [42] NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
    Dyer, Matthew
    Rinaldi, Fiona
    Adler, Amanda I.
    LANCET ONCOLOGY, 2012, 13 (08): : 762 - 763
  • [43] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [44] KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
    Hoimes, Christopher J.
    Graff, Julie N.
    Tagawa, Scott T.
    Hwang, Clara
    Kilari, Deepak
    Ten Tije, A. J.
    Omlin, Aurelius
    McDermott, Raymond S.
    Vaishampayan, Ulka N.
    Elliott, Tony
    Gerritsen, Winald R.
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
    Augustin, Marinela
    Laguerre, Brigitte
    Baldini, Capucine
    Zedan, Ahmed H.
    Gonzalez-Billalabeitia, Enrique
    Fong, Peter C. C.
    Zukov, Ruslan
    Hammerer, Peter
    Prentice, Mark
    Shore, Neal D.
    Necchi, Andrea
    Todenhoefer, Tilman
    Kessler, Elizabeth R.
    Kose, Fatih
    Gurney, Howard
    Valderrama, Begona Perez
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    McDermott, Raymond S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 148 - 148
  • [46] DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC)
    McNeel, Douglas G.
    Eickhoff, Jens C.
    Jeraj, Robert
    Staab, Mary Jane
    Straus, Jane
    Rekoske, Brian
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [47] PHASE 2 TRIAL OF A DNA VACCINE WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    McNeel, Douglas
    Eickhoff, Jens
    Wargowski, Ellen
    Johnson, Laura
    Kyriakopoulos, Christos
    Emamekhoo, Hamid
    Lang, Joshua
    Brennan, Mary Jane
    Liu, Glenn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A377 - A377
  • [48] Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations
    Tsai, Alexander K.
    Kagalwalla, Sana
    Langer, Jenna
    Le-Kumar, Thuy
    Le-Kumar, Vikas
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (1-2) : 51 - 62
  • [49] Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center.
    Roy, Arya Mariam
    Farmer, Bailey
    Kumarasamy, Vasanthan Muthusamy
    Jatwani, Karan
    Levine, Ellis Glenn
    Chatta, Gurkamal S.
    Gopalakrishnan, Dharmesh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [50] Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)
    De Bono, J. S.
    Oudard, S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J. H.
    Shen, L.
    Matthews, P.
    Sartor, A. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345